SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Exelixis, Inc. (EXEL)
An SI Board Since January 2001
Posts SubjectMarks Bans Symbol
930 66 0 EXEL
Emcee:  kinkblot Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
755Just wondering who this guy is: YM - Kaplanbarry39. Given his claim of 36 yearIRWIN JAMES FRANKEL-6/9/2011
754YM by i-rat Would a doc use it today?,,,yes. 23 minutes ago There are aIRWIN JAMES FRANKEL-6/9/2011
753YM kaplanbarry U do nt Understand 9-Jun-11 01:43 pm I have been an oncolIRWIN JAMES FRANKEL-6/9/2011
752YM earnie responds to questions: <<Has there been any discussion on how eIRWIN JAMES FRANKEL-6/8/2011
751Here are the slides: phx.corporate-ir.net I did not describe the cabo effect oIRWIN JAMES FRANKEL-6/7/2011
750>>N=15 evaluating for CTC, with N=3 of CTC<5, N=12 of CTC>5. >&gIRWIN JAMES FRANKEL-6/7/2011
749YM by earnie It is sometimes hard to stay detached and objective while watchingIRWIN JAMES FRANKEL-6/7/2011
748re: <i>Ovarian results were so good that there were not enough patients moIan@SI-6/6/2011
747The webcast was impressive. Bone scans durable (very few progress - 3), confirmIRWIN JAMES FRANKEL-6/6/2011
746I don't think many people expected such a reaction. Was tempted to get back tom pope-6/6/2011
745Exelixis’ Cabozantinib Phase 2 Data Demonstrate Encouraging Clinical Activity inIRWIN JAMES FRANKEL-6/6/2011
744YM by hbomb (very interesting graphics and comments on MET inhibition) Re: CircIRWIN JAMES FRANKEL-6/6/2011
743YM earnie Circulating tumor cells Relevant on a few levels. Dr. Scher is one oIRWIN JAMES FRANKEL-6/6/2011
742Maybe there is no better descriptor in this instance. I was half joking :- )DewDiligence_on_SI-6/6/2011
741roy, what do you expect from a PhII looking at a handful of patients in a largeIan@SI-6/5/2011
740<i>>…in my experience the word "promising" in a biotech compaDewDiligence_on_SI-6/5/2011
739YM onchodoc responds to vin: oncodoc, <<Independent of quotes from respeIRWIN JAMES FRANKEL-6/5/2011
738Exelixis' Cabozantinib Demonstrates Broad Clinical Activity in Multiple TumoIRWIN JAMES FRANKEL-6/5/2011
737With my totally non scientific naive background I should refrain from comment, btom pope-6/4/2011
736The slides linked are interesting: Summary • Cabozantinib demonstrates promisinIRWIN JAMES FRANKEL-6/4/2011
735Exelixis' Cabozantinib Demonstrates Encouraging Clinical Activity in PatientIRWIN JAMES FRANKEL-6/4/2011
734Sounds like convergence with Clarksterh? If the link to OS could be establishedtom pope-6/4/2011
733Yes, but nothing that I consider conclusive proof. Lot of stuff is evidence, weIRWIN JAMES FRANKEL-6/4/2011
732That's short and to the point. Now do we have any evidence yet that <<tom pope-6/3/2011
731A New Perspective On Endpoints in Prostate Cancer Clinical Trials by Celestia HiIRWIN JAMES FRANKEL-6/3/2011
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News